Good morning, and welcome to Stockhead’s Top 10 at shortly-before-11-ish, which is meant to highlight the best (and sometimes worst) performing ASX stocks in morning trade using live data, to provide a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms.

The market opens at 10am (eastern time) and the data is taken at 10:15am, once every ASX stock has started trading – for better or worse – and then I do my best to make sense of who’s moving where and why it might be happening.

Here’s what’s been happening since the doors were opened this morning…

 

WINNERS

Stocks highlighted in yellow have made market-moving announcements (click headings to sort).

Wordpress Table Plugin

 

Alliance Nickel (ASX:AXN) is leading the charge this morning, on news that it’s signed a non-binding term sheet with Samsung – yes, that Samsung – for the future offtake of battery grade nickel and cobalt sulphate products from the NiWest Nickel-Cobalt Project in Western Australia.

Sarytogan Graphite (ASX:SGA) is making headway today after announcing that the first batch of coincell batteries has been produced using the company’s Uncoated Spherical Purified Graphite, which the company says have been outperforming many synthetic graphite anodes that are currently used in electric vehicles.

White Energy (ASX:WEC) has entered into a Farm in Agreement with Aquis listed Tectonic Gold and its local subsidiary Signature Gold in respect of four tenements in the Biloela area of central Queensland which are highly prospective for gold and copper. (This news dropped after hours last night – so it’s technically an announcement for this morning.)

Lanthanein Resources (ASX:LNR) says that an extensive soil sampling programme across its entire 77km2 granted tenement on the Forrestania Greenstone Belt has kicked off, directly adjacent to Covalent Lithium’s (SQM & Wesfarmers) Earl Grey Mine, 189Mt @1.53% Li2O.

Chimeric Therapeutics (ASX:CHM) has announced that the first patient in the ADVENT-AML Phase 1B clinical trial in Acute Myeloid Leukemia (AML) has received treatment with CHM 0201 in combination with Azacitidine and Venetoclax.

 

LOSERS

Stocks highlighted in yellow have made market-moving announcements (click headings to sort).

Wordpress Table Plugin

 

Mamba Exploration (ASX:M24) is showing a loss this morning on news of the successful completion of a share placement to raise $2.75 million via the issue of 110,000,000 fully paid shares at an issue price at A$0.025 per share to sophisticated and professional investors.

Miramar Resources (ASX:M2R) is also showing a dip this morning, despite news that the company has identified multiple very large uranium targets within the Company’s 100%-owned Bangemall Projects, in the Gascoyne region of Western Australia.